Laboratory Characteristics for 23-Year-Old Female with Suspected PCOS
The first-line laboratory tests should be total testosterone (TT) and free testosterone (FT) measured by mass spectrometry, with Free Androgen Index (FAI) as an alternative when mass spectrometry is unavailable 1.
Essential Laboratory Screening
Primary Androgen Assessment
Measure these androgens first:
- Total testosterone (TT) - pooled sensitivity 74%, specificity 86%, AUC 0.87 1
- Free testosterone (FT) - pooled sensitivity 89%, specificity 83%, AUC 0.85 1
- Free Androgen Index (FAI) - pooled sensitivity 78%, specificity 85%, AUC 0.87, and demonstrates the highest diagnostic value in adolescents and young adults 1, 2
The 2025 systematic review and meta-analysis definitively establishes that TT and FT using mass spectrometry provide the best diagnostic accuracy for biochemical hyperandrogenism 1. FAI alone detects 86.5% of PCOS cases; adding TT and androstenedione increases detection to 97.3% 2.
Secondary Androgen Measurements (if TT/FT normal)
If initial testing is negative but clinical suspicion remains high:
- Androstenedione (A4) - sensitivity 75%, specificity 71% (note: poorer specificity) 1
- DHEAS - sensitivity 75%, specificity 67% (note: poorest specificity among androgens) 1
Mandatory Exclusion Tests
All patients require these to exclude PCOS mimics 3:
- TSH - exclude thyroid disease
- Prolactin - exclude hyperprolactinemia (can present with amenorrhea/hirsutism)
- 17-hydroxyprogesterone (17-OHP) - exclude non-classic congenital adrenal hyperplasia (found in 1.5-6.8% of hyperandrogenic patients) 3
Critical pitfall: Significantly elevated testosterone (markedly above normal range) should prompt consideration of NCAH, which requires steroid hormone profiling by mass spectrometry showing elevated 17-OHP and potentially 21-deoxycortisol 4.
Additional Characteristic Laboratory Findings
Gonadotropins
- Elevated LH/FSH ratio >2:1 in 55% of patients, >3:1 in 26.2% 5
- This finding supports diagnosis but is not required
Anti-Müllerian Hormone (AMH)
- Elevated AMH - consistently higher in PCOS phenotypes with polycystic ovarian morphology 6
- Higher AMH associated with oligo-anovulation (OR 1.2, P=0.004) 6
- Important limitation: AMH has limited specificity in adolescents and should not be used as a primary diagnostic criterion in this age group 7
Metabolic Parameters (Common but Not Diagnostic)
Insulin resistance markers:
- Elevated fasting insulin - associated with polycystic ovary morphology (OR 1.11, P=0.013) 6
- Elevated glucose
Lipid abnormalities:
- Elevated triglycerides 6
- Decreased HDL cholesterol - lower HDL associated with polycystic ovary morphology (OR 0.9, P=0.014) 6
Sex hormone binding globulin (SHBG):
- Decreased SHBG is characteristic 2
Emerging Metabolomic Findings
Recent research shows PCOS patients have elevated circulating concentrations of:
- Alanine, leucine, isoleucine, glutamic acid, threonine, acetate, and lactate
- Decreased glutamine and acetone 8
However, these are research findings and not yet standard clinical practice.
Diagnostic Algorithm
Step 1: Measure TT and FT by mass spectrometry (or calculate FAI if mass spectrometry unavailable)
Step 2: Obtain mandatory exclusion labs: TSH, prolactin, 17-OHP
Step 3: If TT/FT/FAI normal but clinical suspicion high, add A4 and DHEAS
Step 4: Assess ovulatory status via menstrual history; consider mid-luteal progesterone if cycles appear regular 3
Step 5: Consider metabolic screening (fasting glucose, insulin, lipid panel) for risk stratification, though not required for diagnosis
Key Diagnostic Considerations
The Rotterdam criteria require 2 of 3 features 3:
- Androgen excess (clinical or biochemical)
- Ovulatory dysfunction
- Polycystic ovarian morphology on ultrasound
At age 23, this patient is past the perimenarchal period where diagnosis is problematic, making standard adult criteria fully applicable 3.
Document which specific features led to the diagnosis, as different phenotypes carry different metabolic and fertility risk profiles 3, 6.